Upstream Bio (NASDAQ:UPB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Upstream Bio (NASDAQ:UPB) from a sell rating to a hold rating in a research note published on Friday morning.

Upstream Bio Price Performance

Shares of NASDAQ:UPB opened at $11.27 on Friday. Upstream Bio has a 12 month low of $5.14 and a 12 month high of $29.46. The company’s 50-day moving average price is $8.60 and its two-hundred day moving average price is $11.30.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.71 million. On average, sell-side analysts expect that Upstream Bio will post -4.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new position in shares of Upstream Bio in the 4th quarter valued at about $25,000. US Bancorp DE bought a new position in shares of Upstream Bio in the 4th quarter valued at about $27,000. Legal & General Group Plc bought a new position in shares of Upstream Bio in the 4th quarter valued at about $28,000. New York State Common Retirement Fund bought a new position in shares of Upstream Bio in the 1st quarter valued at about $29,000. Finally, Summit Investment Advisors Inc. bought a new position in shares of Upstream Bio in the 4th quarter valued at about $30,000.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.